JP2025508943A - ウイルス感染症の治療のための化合物及び方法 - Google Patents
ウイルス感染症の治療のための化合物及び方法 Download PDFInfo
- Publication number
- JP2025508943A JP2025508943A JP2024551973A JP2024551973A JP2025508943A JP 2025508943 A JP2025508943 A JP 2025508943A JP 2024551973 A JP2024551973 A JP 2024551973A JP 2024551973 A JP2024551973 A JP 2024551973A JP 2025508943 A JP2025508943 A JP 2025508943A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharma
- acceptable salt
- ceutically acceptable
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263315919P | 2022-03-02 | 2022-03-02 | |
| US63/315,919 | 2022-03-02 | ||
| US202263413748P | 2022-10-06 | 2022-10-06 | |
| US63/413,748 | 2022-10-06 | ||
| PCT/US2023/014293 WO2023167938A1 (en) | 2022-03-02 | 2023-03-01 | Compounds and methods for treatment of viral infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508943A true JP2025508943A (ja) | 2025-04-10 |
| JP2025508943A5 JP2025508943A5 (cg-RX-API-DMAC10.html) | 2026-03-10 |
Family
ID=85772852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024551973A Pending JP2025508943A (ja) | 2022-03-02 | 2023-03-01 | ウイルス感染症の治療のための化合物及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230322813A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4486746A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025508943A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20240154646A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2023227470A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3243944A1 (cg-RX-API-DMAC10.html) |
| TW (2) | TWI878811B (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023167938A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2595980E (pt) | 2010-07-22 | 2014-11-27 | Gilead Sciences Inc | Métodos e compostos para tratar infeções pelo vírus da família paramyxoviridae |
| EP4219513A1 (en) | 2017-05-01 | 2023-08-02 | Gilead Sciences, Inc. | Crystalline form of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
| TWI785528B (zh) | 2020-03-12 | 2022-12-01 | 美商基利科學股份有限公司 | 1’-氰基核苷之製備方法 |
| US11926645B2 (en) | 2020-08-27 | 2024-03-12 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
| KR20240154647A (ko) | 2022-03-02 | 2024-10-25 | 길리애드 사이언시즈, 인코포레이티드 | 바이러스성 감염 치료를 위한 화합물 및 방법 |
| EP4547665A1 (en) | 2022-06-30 | 2025-05-07 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
| CN119039322A (zh) * | 2023-09-19 | 2024-11-29 | 广东晨康生物科技有限公司 | 一种环碳酸酯核苷化合物的盐、晶体及其制备方法和应用 |
| CN119792537B (zh) * | 2025-01-22 | 2025-10-21 | 常州大学 | 利巴韦林与pd-1抑制剂联合用药物组合物及其应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ105499A0 (en) | 1999-06-18 | 1999-07-08 | Biota Scientific Management Pty Ltd | Antiviral agents |
| AUPR213700A0 (en) | 2000-12-18 | 2001-01-25 | Biota Scientific Management Pty Ltd | Antiviral agents |
| EP1646371A4 (en) | 2003-06-26 | 2010-09-22 | Biotron Ltd | ANTIVIRAL COMPOSITIONS AND METHODS |
| US8669280B2 (en) | 2005-06-24 | 2014-03-11 | Biotron Limited | Antiviral compounds and methods |
| ES2614269T3 (es) | 2007-08-03 | 2017-05-30 | Biotron Limited | Procedimientos y composiciones antivíricas frente a la hepatitis C |
| CA2881322A1 (en) | 2012-09-10 | 2014-03-13 | F. Hoffmann-La Roche Ag | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| MX377523B (es) | 2013-09-11 | 2025-03-10 | Inst Nat Sante Rech Med | Metodos y composiciones farmaceuticas para el tratamiento de la infeccion por el virus de la hepatitis b. |
| PE20160686A1 (es) | 2014-01-30 | 2016-07-23 | Hoffmann La Roche | Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infeccion por virus de la hepatitis b |
| PL3114128T3 (pl) | 2014-03-07 | 2019-06-28 | F. Hoffmann-La Roche Ag | Nowe skondensowane w pozycji 6 heteroarylodihydropirymidyny stosowane w leczeniu i profilaktyce zakażenia wirusem zapalenia wątroby typu B |
| CN106459032B (zh) | 2014-05-13 | 2019-04-05 | 豪夫迈·罗氏有限公司 | 治疗和预防乙型肝炎病毒感染的新的二氢喹嗪酮类 |
| WO2016012470A1 (en) | 2014-07-25 | 2016-01-28 | F. Hoffmann-La Roche Ag | New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid |
| JP6506836B2 (ja) | 2014-08-14 | 2019-04-24 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｂ型肝炎ウイルス感染症の処置および予防のための新規ピリダゾンおよびトリアジノン |
| US9637485B2 (en) | 2014-11-03 | 2017-05-02 | Hoffmann-La Roche Inc. | 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection |
| WO2016102438A1 (en) | 2014-12-23 | 2016-06-30 | F. Hoffmann-La Roche Ag | Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidine analogues |
| US9676793B2 (en) | 2014-12-23 | 2017-06-13 | Hoffmann-Laroche Inc. | Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same |
| EP3240537B1 (en) | 2014-12-30 | 2020-09-09 | F. Hoffmann-La Roche AG | Novel tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis b virus infection |
| CN107109497A (zh) | 2014-12-31 | 2017-08-29 | 豪夫迈·罗氏有限公司 | 通过实时PCR从细胞裂解物定量HBV cccDNA的高通量新方法 |
| MA41338B1 (fr) | 2015-01-16 | 2019-07-31 | Hoffmann La Roche | Composés de pyrazine pour le traitement de maladies infectieuses |
| EP3250685A1 (en) | 2015-01-27 | 2017-12-06 | F. Hoffmann-La Roche AG | Recombinant hbv cccdna, the method to generate thereof and the use thereof |
| JP6435054B2 (ja) | 2015-02-11 | 2018-12-05 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｂ型肝炎ウイルス感染の治療及び予防のための新規２−オキソ−６，７−ジヒドロベンゾ［ａ］キノリジン−３−カルボン酸誘導体 |
| WO2017184668A1 (en) * | 2016-04-20 | 2017-10-26 | Gilead Sciences, Inc. | Methods for treating flaviviridae virus infections |
| BR112019016316A2 (pt) | 2017-02-08 | 2020-03-31 | Biotron Limited | Métodos para o tratamento da influenza |
| KR20220132608A (ko) * | 2020-01-27 | 2022-09-30 | 길리애드 사이언시즈, 인코포레이티드 | SARS CoV-2 감염증을 치료하기 위한 방법 |
| TWI791193B (zh) * | 2020-02-18 | 2023-02-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| CN112778310B (zh) * | 2020-04-20 | 2025-05-30 | 中国科学院上海药物研究所 | 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用 |
| IL299202A (en) * | 2020-06-24 | 2023-02-01 | Gilead Sciences Inc | 1'-cyano nucleoside analogs and uses thereof |
| US11926645B2 (en) * | 2020-08-27 | 2024-03-12 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
| CN116370479B (zh) * | 2020-12-30 | 2024-02-13 | 南方科技大学 | 化合物atv014在制备用于治疗新冠病毒感染的产品中的用途 |
| US20240166680A1 (en) * | 2021-04-15 | 2024-05-23 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Nucleoside analog and use thereof |
| CN114181258B (zh) * | 2021-12-29 | 2023-10-13 | 南京师范大学 | 用于抗病毒治疗的核苷类化合物及用途 |
| CN114437159B (zh) * | 2022-04-11 | 2022-06-28 | 佛山市晨康生物科技有限公司 | 一种环状碳酸酯核苷类化合物及其应用 |
-
2023
- 2023-03-01 JP JP2024551973A patent/JP2025508943A/ja active Pending
- 2023-03-01 TW TW112107366A patent/TWI878811B/zh active
- 2023-03-01 US US18/115,895 patent/US20230322813A1/en active Pending
- 2023-03-01 EP EP23713504.1A patent/EP4486746A1/en active Pending
- 2023-03-01 CA CA3243944A patent/CA3243944A1/en active Pending
- 2023-03-01 WO PCT/US2023/014293 patent/WO2023167938A1/en not_active Ceased
- 2023-03-01 TW TW114109499A patent/TW202525811A/zh unknown
- 2023-03-01 KR KR1020247032560A patent/KR20240154646A/ko active Pending
- 2023-03-01 AU AU2023227470A patent/AU2023227470A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202525811A (zh) | 2025-07-01 |
| US20230322813A1 (en) | 2023-10-12 |
| AU2023227470A1 (en) | 2024-08-29 |
| KR20240154646A (ko) | 2024-10-25 |
| TWI878811B (zh) | 2025-04-01 |
| EP4486746A1 (en) | 2025-01-08 |
| WO2023167938A1 (en) | 2023-09-07 |
| TW202345786A (zh) | 2023-12-01 |
| CA3243944A1 (en) | 2023-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11814406B2 (en) | Compounds and methods for treatment of viral infections | |
| TWI878811B (zh) | 用於治療病毒感染的化合物及方法 | |
| TWI867455B (zh) | 用於治療病毒感染的化合物及方法 | |
| JP7633394B2 (ja) | リン脂質化合物及びその使用 | |
| EP4536223A1 (en) | Methods for treatment of viral infections including sars-cov-2 | |
| JP2024109964A (ja) | リン脂質化合物及びその使用 | |
| AU2024353008A1 (en) | Compounds and methods for treatment of viral infections | |
| TWI851054B (zh) | 抗病毒化合物及其製造及使用方法 | |
| CN118786127A (zh) | 用于治疗病毒感染的化合物和方法 | |
| HK40113783A (en) | Compounds and methods for treatment of viral infections | |
| HK40115603A (en) | Compounds and methods for treatment of viral infections | |
| HK40096334B (en) | Compounds and methods for treatment of viral infections | |
| HK40096334A (en) | Compounds and methods for treatment of viral infections | |
| EA048943B1 (ru) | Соединения и способы лечения вирусных инфекций |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260302 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260302 |